<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>phase 2/3 trial &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/phase-2-3-trial/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 21 Oct 2026 12:39:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>phase 2/3 trial &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>U.S. trial tests ivonescimab for advanced biliary tract cancer</title>
		<link>https://bioengineer.org/u-s-trial-tests-ivonescimab-for-advanced-biliary-tract-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 21 Oct 2026 12:39:25 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[announces]]></category>
		<category><![CDATA[biliary tract cancer]]></category>
		<category><![CDATA[chemoimmunotherapy]]></category>
		<category><![CDATA[ECOG-ACRIN]]></category>
		<category><![CDATA[ivonescimab]]></category>
		<category><![CDATA[national]]></category>
		<category><![CDATA[National Cancer Institute]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[PD-1]]></category>
		<category><![CDATA[phase 2/3 trial]]></category>
		<category><![CDATA[trial]]></category>
		<category><![CDATA[VEGF]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=446275</guid>

					<description><![CDATA[A National Cancer Institute-funded phase 2/3 trial will test ivonescimab plus chemotherapy against standard chemoimmunotherapy in U.S. patients with advanced biliary tract cancer.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">446275</post-id>	</item>
	</channel>
</rss>
